Table 2.
Detailed summary of characteristics of SARS-CoV-2 mRNA vaccine nonresponders (n=21)
| Age | Sex | Race | Ethnicity | Notable Comorbid Conditions | Prescribed Medications Affecting Immune Function | Days from Vaccine Second Dose to Ab Test | Clinical Event within 14 d of COVID Vaccination | |
|---|---|---|---|---|---|---|---|---|
| Hospitalization | Other Vaccine | |||||||
| 40s | F | Black | Unknown | DM, CHF, hepatitis B, PVD, active bacterial infection | None | 14 | Yes | None |
| 50s | F | White | Non-Hispanic | Thyrotoxicosis, bipolar disorder, depression | None | 35 | None | None |
| 50s | F | White | Non-Hispanic | HIV, bipolar disorder, illicit drug use, cervical CA history | Lamivudine, dolutegravir, ritonavir, darunavir | 19 | None | None |
| 50s | F | White | Non-Hispanic | DM, CHF, hypothyroid | None | 39 | None | None |
| 60s | F | Unknown | Unknown | DM, CHF, Lyme disease, depression, osteoarthritis, gout, uterine CA history | None | 32 | None | None |
| 60s | F | Unknown | Non-Hispanic | DM | None | 19 | Yes | None |
| 60s | F | White | Unknown | A fib, CHF, breast CA history | None | 20 | Yes | None |
| 60s | F | Native American | Non-Hispanic | DM | None | 27 | Yes | Heplisav |
| 60s | F | Native American | Non-Hispanic | DM, seizure disorder, CVA, PVD, depression, calciphylaxis | None | 41 | None | None |
| 70s | F | Black | Non-Hispanic | SLE, prior transplant, SVC syndrome | Hydroxychloroquine, prednisone | 17 | None | None |
| 70s | F | White | Non-Hispanic | DM, gout, osteoarthritis, prior transplant | Prednisone, tacrolimus | 19 | None | None |
| 70s | F | Asian | Non-Hispanic | CHF, SLE, hepatitis B, osteoarthritis, colon CA history | Prednisone, mycophenolate, hydroxychloroquine, entecavir | 19 | None | None |
| 70s | M | Unknown | Unknown | DM, GERD, prior transplant | Prednisone, tacrolimus, mycophenolate, thymoglobulina | 17 | Yes | Prevnar |
| 70sb | M | White | Non-Hispanic | DM, A fib, depression | None | 14 | None | None |
| 70s | F | White | Unknown | DM, depression, COPD | None | 38 | Yes | None |
| 70s | M | White | Non-Hispanic | DM, hypothyroid, gout, neuropathy, Melanoma CA history, | None | 25 | Yes | Heplisav |
| 70sc | M | Black | Non-Hispanic | DM, CHF, DVT, BPH, GERD, gout | None | 24 | Yes | Heplisav |
| 80s | F | White | Non-Hispanic | DM, CHF, CAD, hypothyroid, gout, depression | None | 39 | Yes | None |
| 80s | F | White | Hispanic | DM, A fib, CHF, hypothyroid | None | 41 | Yes | None |
| 80s | M | White | Non-Hispanic | DM, A fib, CHF, COPD, gout | Hydroxychloroquine | 21 | Yes | None |
| 80s | M | Unknown | Non-Hispanic | DM, A fib, CHF, hypothyroid, COPD | None | 23 | Yes | None |
F, female; DM, diabetes mellitus; CHF, congestive heart failure; PVD, peripheral vascular disease; CA, cancer; A fib, atrial fibrillation; CVA, cerebro-vascular accident; M, male; SLE, systemic lupus erythromatosus; GERD, gastroesophageal reflux disease; BPH, benign prostatic hypertrophy; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease.
a
Communicated by nephrologist.
b
Received Moderna vaccine, all others received Pfizer vaccine.
c
Peritoneal dialysis modality, all others utilized hemodialysis.